ROTFL. Three treated. One discharged. Two in early stage rehab. Statistically meaningless results, An absolute joke announcement.
These drugs (synthetic melanocortins) have been around for over 50 years years. There has been a huge amount of hype about treating a very wide range of medical conditions. But decades of clinical trials have had very little success. They have an extremely high rate (>10%) of unpleasant side effects. The only practical use found so far is creating sunless tans (that is how Scenesse actually 'treats' EPP). That is why Big Pharma has shown almost no interest in them.
Ann: Afamelanotide well tolerated by first stroke patients, page-8
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |